This antiviral stainless steel can inactivate 99.75 per cent of SARS-CoV-2 virus within three hours and is expected to replace frequently touched stainless steel products in public areas to reduce...
CP-COV03, a niclosamide-based oral antiviral drug, may be combined with dexamethasone to raise efficacy 2.1 times. Experimental results have been published for the first time showing that an...
Researchers at Columbia University Irving Medical Center identify neutralizing antibodies against SARS-CoV-2 virus from COVID-19 Patients. The human body’s immune response to an infection involves...
High-resolution cryo-EM structures of Remdesivir-bound SARS-CoV-2 have been imaged, providing mechanism insights and facilitating drug design efforts to combat the virus. SARS-CoV-2, the virus...
Gilead Sciences Inc. announced on 13 April 2020 results showing clinical improvements in 68 percent of 53 hospitalized patients with severe complications of COVID-19. Remdesivir is an investigational...